This is supported by the first scientific evidences demonstrating the feasibility of 6-month follow-ups using REMS to quantify the BMD decrease due to aromatase inhibitors-based treatment in breast cancer patients, and to assess the BMD recovery following denosumab administration [17, 18]. This evidence concerns the gene CYP19A1 and breast cancer.